Latest research on Dasatinib

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Dasatinib indications

To the best of our knowledge, this was the first study to evaluate the potential therapeutic effects of Dasatinib on lung function, inflammation, and remodeling in experimental silicosis. [source, 2016]
Besides its effect on malignant cells, Dasatinib also blocks certain functions of various hematopoietic cells by inhibiting T lymphocyte activation and proliferation [8], suppressing natural killer cell toxicity [9], blocking allergen-induced release of histamine in blood basophils [10], affecting platelet activation [11] and reducing neutrophil activation and chemotaxis [12,13]. [source, 2016]
Moreover, these inflammatory changes may be related to the effect of Dasatinib in reducing the number of M1 macrophages and increasing the number of M2 macrophages in lung parenchyma and granuloma of silicotic mice. [source, 2016]
Dasatinib, a second-generation TYROSINE kinase inhibitor, was chosen for our study because it is safe, presents potent antifibrotic effects, and has a lower cost [8]. [source, 2016]
The therapeutic effects of Dasatinib on peritoneal dissemination were tested in a xenograft mouse model. [source, 2016]
We transfected the pGL4.51 (luc2/CMV/Neo) vector into 58As9 cells to evaluate the in vivo effects of Dasatinib with an IVIS imaging system. [source, 2016]
Both orally and intraperitoneally administered Dasatinib effectively suppressed the peritoneal metastasis of GC (Fig. 5a–c), leading to significantly longer survival times in Dasatinib-treated mice than those in control mice (Fig. 5d). [source, 2016]
The aims of the current study were to evaluate whether SFKs and downstream markers of activation were associated with ccRCC patient prognosis and to investigate the functional effects of two SFK inhibitors, Dasatinib and saracatinib, in non-metastatic and metastatic ccRCC cell lines. [source, 2016]
In the early non-metastatic, 769-P and 786-O ccRCC cell lines, Dasatinib significantly inhibited SFK phosphorylation at Y419, however saracatinib has no effect. [source, 2016]
We also examined the effect of a TYROSINE kinase inhibitor, Dasatinib, which inhibits DDR1 with an IC50 of 1.35 nM (Day ). [source, 2015]